SPTX
Seaport Therapeutics, Inc. Common StockHealthcare · $1.1B market cap
Verdict
We can't put a fair value on SPTX right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow SPTX
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Nov 3, 2026: 1 open-market purchase worth $99K. Why purchases matter
Purchases
Questions about SPTX
Are insiders buying SPTX?
Since Nov 3, 2026: 1 open-market purchase worth $99K.
How can I check SPTX's value myself?
Use the free Sticker Price calculator, already filled with SPTX's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 4, 2026. How the Payback Price works